The Bioactives Committee seeks to expand the quality of evidence linking health-promoting dietary components with health outcomes and advance translation into dietary guidance by promoting quality research, supporting evidence-based scientific reviews, and partnering with health authorities as they translate science broadly into recommendations for public health benefit.
What are Bioactives?
Bioactives are constituents in foods, other than those to meet basic nutritional needs, that are responsible for a change in human health.(Office of Disease Prevention & Health Promotion)
Why is this important?
Science points to the health benefits of food components beyond traditionally accepted “essential” nutrients, yet there is no framework around which to base dietary guidance. It is critical to understand the level of bioactive intake that produces a health effect. The committee is developing guidelines to promote the appropriate methods and terminology when designing and reporting flavonoid research. Harmonization in the literature is critical to building the evidence body needed to support dietary guidance.
DSM Nutritional Products
Ocean Spray Cranberries, Inc.
Ex-Officio: Florida Department of Citrus
John Erdman, PhD, University of Illinois
Johanna Dwyer, DSc, RD, Tufts Medical Center
Janet Novotny, PhD, US Department of Agriculture
This systematic review and meta-analysis examines, for the first time, if there is consistent evidence that higher flavan-3-ol intake, irrespective of source, reduces cardiometabolic risk.
See how the IAFNS Bioactives Committee is challenging the next generation of nutrition scientists to find innovative ways to include safety measures in nutrition research.
The purpose of this research was to summarize the data related to lutein/zeaxanthin intake and visual outcomes in adults with healthy eyes using evidence mapping methods and to describe the research to date that would be useful in guiding future research priorities, systematic reviews, and meta-analyses.
The authors of this study examined, for the first time, if there is consistent evidence that higher flavan-3-ol intake, irrespective of dietary source, reduces cardiometabolic risk.
Through evidence mapping, this study determined the extent of the evidence base to initiate a future systematic review investigating the impact of flavan-3-ol intake on CVD and diabetes outcomes.